J&J study data show dramatic benefit to multiple myeloma cell therapy
A study abstract inadvertently posted online showed J&J and Legend’s therapy, Carvykti, reduced the risk of disease progression or death by more than 70% over standard drugs.
J&J study data show dramatic benefit to multiple myeloma cell therapy Read More »
